Eli Lilly advanced its blood cancer strategy by presenting early clinical data for AJ1-11095, a type II JAK2 inhibitor in development for myelofibrosis that originated from its acquisition of Ajax Therapeutics. At EHA 2026 in Stockholm, Lilly shared encouraging updates supporting continued development of the asset. The focus on AJ1-11095 underscores Lilly’s intent to translate acquisition-driven assets into differentiated offerings in hematologic malignancies, particularly where JAK pathway competition and unmet need remain intense. The early readouts will be assessed against existing JAK inhibitors and evolving combination approaches. Separate from the broader acquisition headlines, the EHA disclosures serve as a near-term scientific checkpoint that can influence both valuation and partner interest across JAK and myelofibrosis adjacencies.